Enlivex's GVHD drug Apocell wins orphan status from FDA

04/5/2013 | Globes (Israel)

The FDA has granted orphan-drug designation to Enlivex Therapeutics' Apocell, an experimental drug for graft-versus-host disease. The designation will give the drug seven years of market exclusivity and "significant regulatory easements, which we believe will shorten marketing approval of the drug in the US, reducing costs," Enlivex CEO Alon Moran said.

View Full Article in:

Globes (Israel)

Published in Briefs:

SmartBrief Job Listings for Health Care